Taking vitamin K along with standard liver cancer treatment cuts the risk of the cancer coming back by about 74%. This means patients who take vitamin K are much less likely to see their cancer return.
See the scientific wording
Vitamin K supplementation, when used as an adjunctive therapy in patients with hepatocellular carcinoma, is associated with a 74% reduction in the risk of recurrence, as indicated by a pooled hazard ratio of 0.26 (95% confidence interval: 0.15–0.46), suggesting a strong protective effect against cancer recurrence.
Very strong evidence
One moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis2026
This study looked at many patients with liver cancer and found that taking vitamin K along with treatment reduced the chance of the cancer coming back by a large amount.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Vitamin K2 helps stop liver cancer from coming back by blocking two important signals that cancer cells need. It stops a protein that makes cancer cells grow and multiply, and it also stops the tumor from building new blood vessels to feed itself. This slows down the cancer and lowers the chance of it returning.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Taking vitamin K along with standard liver cancer treatment cuts the risk of the cancer coming back by about 74%. This means patients who take vitamin K are much less likely to see their cancer return.
Mechanism
1 studyVitamin K2 works in two main ways to stop liver cancer from coming back. It blocks a signal that makes cancer cells grow, and it also stops the tumor from making new blood vessels to get food. This slows the cancer down and makes it less likely to return.
Vitamin K2 helps stop liver cancer from coming back by blocking two important signals that cancer cells need. It stops a protein that makes cancer cells grow and multiply, and it also stops the tumor from building new blood vessels to feed itself. This slows down the cancer and lowers the chance of it returning.
Vitamin K2 inhibits IKK kinase activity, preventing IκB phosphorylation and blocking NF-κB activation.
Reduced NF-κB activation leads to decreased cyclin D1 expression, slowing cell cycle progression and tumor growth.
Vitamin K2 inhibits PKC and PKD1, activating the PKA/p53 pathway and promoting p21 transcription, which causes cell cycle arrest.
Vitamin K2 downregulates the expression of HCC-derived growth factor, further suppressing tumor proliferation.
Vitamin K2 inhibits VEGFR2 phosphorylation, blocking angiogenesis signaling that is induced by hypoxic conditions after TACE, preventing the formation of new blood vessels that support tumor growth.
Evidence from Studies
Supporting (1)
Community contributions welcome
The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis
This study looked at many patients with liver cancer and found that taking vitamin K along with treatment reduced the chance of the cancer coming back by a large amount.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Vitamin K Supplementation on Recurrence Risk in Hepatocellular Carcinoma
A systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies comparing vitamin K supplementation versus placebo or no supplementation in patients with hepatocellular carcinoma, with recurrence as the outcome, including subgroup analyses for dose and duration.
Randomized Controlled Trial of Vitamin K as Adjunctive Therapy in Hepatocellular Carcinoma: Effect on Recurrence
A double-blind, placebo-controlled trial with patients with hepatocellular carcinoma after curative treatment (e.g., resection or ablation), randomized to vitamin K (specified dose) or placebo for a defined duration (e.g., 2 years), with recurrence-free survival as the primary endpoint.
Prospective Cohort Study of Vitamin K Use and Recurrence in Hepatocellular Carcinoma Patients
A prospective cohort study enrolling patients with hepatocellular carcinoma at diagnosis or after treatment, documenting vitamin K supplementation (including dose and duration), and following them for recurrence, using Cox proportional hazard models to adjust for confounders.
Case-Control Study of Vitamin K Supplementation and Risk of Recurrence in Hepatocellular Carcinoma
A retrospective case-control study within a cohort of HCC patients: cases are those with recurrence, controls are matched patients without recurrence; define vitamin K supplementation exposure via medical records or interviews, adjusting for matching factors and confounders.